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Abstract: Extraintestinal manifestations of Clostridioides difficile infections (CDIs) are very 
uncommon, and according to the literature, poor outcomes and a high mortality have been observed 
among affected individuals. The objective of this study was to investigate the incidence rate of 
extraintestinal infections caused by C. difficile (ECD) in a tertiary-care university hospital in 
Hungary. During a 10-year study period, the microbiology laboratory isolated 4129 individual 
strains of C. difficile; among these, the majority were either from diarrheal fecal samples or from 
colonic material and only n = 24 (0.58%) were from extraintestinal sources. The 24 extraintestinal C. 
difficile isolates were recovered from 22 patients (female-to-male ratio: 1, average age: 55.4 years). 
The isolates in n = 8 patients were obtained from abdominal infections, e.g., appendicitis, rectal 
abscess or Crohn’s disease. These extraintestinal cases occurred without concomitant diarrhea. In 
all, but two cases C. difficile was obtained as a part of a polymicrobial flora. Our isolates were 
frequently toxigenic and mostly belonged to PCR ribotype 027. Resistance to metronidazole, 
vancomycin, clindamycin and rifampin were 0%, 0%, 20.5% and 9.7%, respectively. The increasing 
amount of reports of C. difficile extraintestinal infections should be noted, as these infections are 
characterized by a poor outcome and high mortality rate. 
Keywords: Clostridioides difficile; extraintestinal; infection; bacteremia; intraoperative infections; 
abscess; wound infection; epidemiology; anaerobes 
 
1. Introduction 
Clostridioides difficile (formerly Clostridium difficile, Cd) is a Gram-positive, spore-forming, 
anaerobic bacillus, which is commonly found in the intestinal tract of animals and humans and in the 
environment [1]. The bacteria could produce exotoxins, namely toxin A (tcdA), toxin B (tcdB) and 
binary toxin (CDT); the toxin-producing strains are the common cause of antibiotic-associated 
diarrhea (AAD), accounting for 15%–25% of all episodes of AAD [2]. Risk factors associated with 
transmission are exposure to antibiotics (especially broad-spectrum agents, e.g., amoxicillin-
clavulanic acid, clindamycin and fluoroquinolones), gastrointestinal surgery/manipulation, an 
extended stay in hospital, serious underlying illnesses (e.g., immunosuppression and cancer) and 
advanced age. In the last several decades, the frequency and severity of intestinal Cd infections (CDIs) 
have been increasing worldwide to become one of the most common and serious hospital-acquired 
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infections (HAIs) [3]. In 2002, an outbreak in Quebec, Canada, demonstrated the emergence of a 
virulent strain type known as the North American pulsed-field gel electrophoresis type 1 (NAP1 or 
PCR ribotype 027) [4]. This strain type was associated with an increase in the number of Cd outbreaks 
in hospitals with higher rates of recurrence and mortality and it also stressed the importance of 
research in the field of microbiology, epidemiology and infection control [5]. Cd may be a causative 
agent in infections outside the intestine, but there is very little information available about 
extraintestinal infections caused by this pathogen. Nevertheless, with an increase in the incidence of 
Cd-associated colitis, there has also been a similar increase in cases of extraintestinal (or extracolonic) 
Cd. 
Extraintestinal CDIs are rare but their clinical role has been reported by Smith and King in 1962 
[6], much sooner, than the recognition of the significance of Cd in enterocolitis. Most extracolonic 
infections of Cd are preceded by gastrointestinal disease, either Cd colitis or surgical and/or 
anatomical disruption of the colon. In real-life clinical situations, delineating the pathogenic role of 
Cd in an extraintestinal site is often problematic and questionable. Evaluation of the significance of 
these bacteria is not always straightforward, especially if the strain is found as a part of a mixed 
infection. The epidemiology of extraintestinal Cd infections may vary greatly by region and time 
period; therefore, the assessment of local/institutional data is essential to evaluate the regional or 
national situation and to reflect on international data available [7]. With this in mind, the aim of the 
present study was to perform a systematic analysis of all consecutive extraintestinal CDI cases over 
a 10-year study period to establish a complete spectrum of infection as well as the clinical significance 
of Cd, and to report all extraintestinal Cd isolated in our institution during the last 10 years. 
2. Results 
During the 10-year study period, the Institute of Clinical Microbiology has isolated 4129 
individual isolates of Cd. Overwhelming majority of these isolates were either from diarrheal fecal 
samples or from colonic material (n = 4104, 99.42%). After our first recorded case of clinically relevant 
extraintestinal Cd, the detailed epidemiological characterization of these infections was performed 
[8]: only n = 24 (0.58%) was isolated from extraintestinal sources (corresponding to 0.003 cases/1000 
patients). The number of extraintestinal CDI cases was 2.2 ± 1.3/year (range: 0–4; with highest 
numbers in 2009 and 2011 [n = 4], while no cases were recorded in 2015). Most of the extraintestinal 
Cd containing-samples originated from the Dept. of Surgery (n = 12), while n = 3 samples had come 
from the Dept. of Dermatology and Immunology, Dept. of Pediatrics and Dept. of Internal Medicine 
and n = 1 sample from the Dept. of Obstetrics and Gynecology, Dept. of Maxillofacial and Oral 
Surgery and Dept. of Urology, respectively. The majority of isolates were recovered from superficial 
and deep wound exudates (n = 6 and n = 4, respectively) and abscesses (n = 6), additionally, n = 3 
isolated originated from the abdominal cavity or were taken intra-operatively, while an isolate each 
was also recovered from a blood culture sample, bile sample and a blister fluid (n = 3 overall). 
The 24 extraintestinal Cd isolates were recovered from 22 patients (males and females in equal 
measure), with an average age of 55.4 years (range: 9 months–84 years); n = 10 patients were over 65 
years of age. Most of the patients were suffering from co-morbidities and severe underlying illnesses 
(Table 1) and only n = 8 patients were outpatients; four out of eight outpatients were affected by a 
skin- and soft tissue infection. In the case of eight patients, the focus of infection was abdominal 
(appendicitis, abscess in the colon and Crohn’s disease), while for seven patients, Cd was found in a 
dermatological abscess or wound. At the time of isolation, none of the patients presented with 
diarrheal illness, for this reason, clinicians did not request the examination of a stool sample for Cd. 
In most cases, Cd strains were isolated together with other aerobic, facultative anaerobic or 
obligate anaerobic bacteria (n = 20), Cd was the only isolated species in n = 4 samples only (two 
individual samples from two different patients, and two individual samples from a third patient), 
namely a blood culture, an intraoperatively-collected gynecological sample and two samples from a 
renal abscess. The most frequently detected co-pathogens were Escherichia coli (n = 6) and Enterococcus 
faecalis/faecium (n = 6), respectively (Table 1). 
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Table 1. Data of patients with extraintestinal Cd infections, 2008–2017. 
Year of 
Isolation 
Dept. or Ward O/I Sex Age 
Disease/Indication for Sample 
Submission 
Sample of Interest 
A/B 
Toxin 
RT 
Co-Pathogens 
Isolated 
2008 
Surgery I M 82 Acute appendicitis Surgical sample + 078 
E. faecium 
Veillonella spp. 
Candida 
tropicalis 
Pediatric ICU I F 
9 
months 
Invagination of the bowel Puncture for abdominal cavity + 011 
Bacteroides 
vulgatus 
B. uniformis 
C. ramosum 
2009 
Maxillofacial and Oral 
Surgery 
O F 38 Inflammation of the salivary gland Abscess − n.d. 
Streptococcus 
viridans 
Campylobacter 
ureolyticus 
Prevotella 
buccae 
Peptostreptococ
cus anaerobius 
Veillonella spp. 
Urology O F 37 
Inflammation of the skin and 
subcutaneous tissue 
Superficial wound exudate + 198 
Actinomyces 
meyeri 
C. ureolyticus 
P. anaerobius 
P. 
melaninogenica 
Surgery I M 69 Gangrene Surgical sample − n.d. 
A. prevotii 
P. buccae 
P. intermedia 
Dermatology O M 60 
Varicose veins of the lower limbs with 
ulceration 
Abscess − n.d. 
S. pyogenes 
Staphylococcus 
aureus 
C. ureolyticus 
Cutibacterium 
acnes 
Eubacterium 
limosum 
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Craterellusfalla
x 
2010 
Surgery I M 58 Gallstone disease Bile + 027 C. bifermentas 
OB/GYN I F 54 Abnormal uterine and vaginal bleeding Deep wound exudate  + 198 - 
Dermatology O M 22 Erythema intertrigo Superficial wound exudate − 488 
S. aureus 
P. anaerobius 
C. ureolyticus 
E. lentum 
Mobiluncus 
spp. 
2011 
Cardiology I F 80 Disorders of the electrolyte balance Blood culture + 027 - 
Surgery O F 22 Rectal abscess Abscess + 027 
C. albicans 
E. coli 
S. pyogenes 
P. bivia 
P. oralis 
P. anaerobius 
E. limosum 
Pediatrics O M 17 Therapy-resistant Crohn’s disease Abscess + 018 
S. 
acidominimus 
E. coli 
P. anaerobius 
Finegoldia 
magna 
C. bifermentans 
P. 
melaninogenica 
Surgery O F 80 Abdominal pain Surgical sample + 027 
S. pyogenes 
Morganella 
morganii 
P. anaerobius 
B. fragilis 
2012 
ICU I M 84 Septicemia Blister fluid n.d. n.d. 
Acinetobacter 
spp. 
C. acnes 
Surgery I M 70 Malignant tumor of the flexura lienalis  Surgical sample + 027 
E. coli 
E. faecium 
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Pseudomonas 
aeruginosa 
E. lenta 
B. fragilis 
2013 
ICU I M 60 
Myasthenia gravis, chronic kidney 
failure 
Deep wound exudate (n = 2) n.d. n.d. 
P. mirabilis 
P. 
melaninogenica 
B. fragilis 
B. ovatus 
Surgery I F 32 Abscess in and around the kidneys 
Abdominal puncture sample (n 
= 2) 
+ 027 - 
2014 
Internal Medicine I F 81 Ventricular fibrillation and flutter Abscess n.d. n.d. 
E. coli 
E. faecalis 
A. vaginalis 
B. uniformis 
Surgery I M 68 
Localized infections of the skin and 
subcutaneous tissue 
Deep wound exudate (n = 2) + 198 
P. mirabilis 
E. coli 
E. faecalis 
F. magna 
P. anaerobius 
B. fragilis 
2016 Dermatology O F 80 Ulceration of the lower limbs Superficial wound exudate + n.d. 
P. aeruginosa 
S. dysgalactiae 
P. anaerobius 
Lactobacillus 
spp. 
2017 
Surgery I M 40 Unknown disease of the pancreas Abdominal puncture sample + 027 
E. coli 
E. faecium 
S. aureus 
B. vulgatus 
P. merdae 
Surgery I F 83 
Localized infections of the skin and 
subcutaneous tissue 
Superficial wound exudate + n.d. 
E. faecalis 
F. nucleatum 
C. histolyticum 
A. vaginalis 
Legend: O: outpatient; I: inpatient; ICU: intensive care unit; OB/GYN: obstetrics and gynecology; RT: ribotype; n.d.: not determined; +/−: presence/absence of toxins. 
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Interestingly, in a 38-year-old female patient attending the Dept. of Maxillofacial and Oral Surgery 
with an infected salivary gland (sample obtained with sterile puncture), Cd was found as a member of a 
complex bacterial flora, while in a 54-year old female patient, Cd was the only isolated pathogen in very 
high CFU/mL, corresponding to a case of pelvic inflammatory disease (PID), where a surgical sample was 
taken in the context of aberrant uterine and vaginal bleeding. In case of two patients, Cd was isolated on 
two separate occasions: one patient was a 60-year-old male in the ICU where Cd was found as a part of a 
mixed anaerobic flora in two decubitus wound exudates, and a 32-year-old female, where only a ribotype 
027 strain was isolated in high colony forming units from two independent samples of a renal abscess (Table 
1). 
Toxin-production of the respective isolates was determined in 19 cases; 15 out of 19 isolates tested 
(79%) were toxin A and toxin B-positive. Ribotyping was performed in 14 cases: seven tested isolates (50%) 
were corresponding to the hypervirulent 027 PCR ribotype, while three strains were of the 198 PCR 
ribotype, which is very rarely found in other countries, as it is very specific to the region of the study. 
Antibiotic susceptibility testing was performed in respect to all isolates for metronidazole (MET), 
vancomycin (VAN), clindamycin (CLI) and rifampicin (RIF). MET and VAN susceptibility was 100% 
(24/24), resistance rate against and CLI was 20.5% (5/24), while 9.7% for RIF (2/24). 
3. Discussion and Review of the Literature 
The results of our present study highlight already existing data on the infrequent occurrence of the 
extraintestinal manifestations of CDIs. Extraintestinal Cd infections were observed sporadically among 
patients hospitalized in our university hospital in Szeged between the 1 January 2008 and 31 December 
2017. Previously, we reported a rare extraintestinal infection caused by toxigenic Cd in a 31-year-old male 
patient admitted to the hospital, who was a victim of an accident and was subsequently polytraumatized 
[8]. He injured his lower limbs harvesting potato; thus, his lacerated wounds were grossly contaminated by 
soil. Microbiological examination of the pus revealed a toxin-producing Cd as an etiological agent of this 
infection: culture from the lateral wound sample showed the presence of a high CFU/mL of a toxin-
producing Cd strain by anaerobic incubation and few colonies of Bacillus subtilis strain by aerobic 
incubation. After the molecular genetic investigation, the strain proved to be a 014-PCR ribotype and XVIII. 
toxinotype, A and B toxin-positive, and binary toxin-negative strain by PCR methods and sequencing [8]. 
Our patient was not immunocompromised; he had no history of diabetes, malignancy and gastrointestinal 
disorders. Our patient had none of the well-known risk factors of recent hospitalization and broad-spectrum 
antibiotic use prior to the extraintestinal manifestations; in line with this, there are increased reporting of 
abscesses caused by this the organism in the absence of diarrhea: this is a concerning finding and may be a 
sign of the emergence of new toxigenic strains in the asymptomatic carriers. 
Extraintestinal infection due to Cd is a rare finding and these are usually reported in the form of case 
reports. Until now, there are only some case reports in the literature: Jacobs et al. described extracolonic Cd 
infections of the small bowel and reactive arthritis [9] and reviewed the literature in 2001. In this publication, 
they have found that preceding invasive interventions are often associated with the involvement of the 
small intestine, corresponding to a high mortality rate (4/7 patients), especially if concomitant bacteremia is 
also present. These infections were usually of polymicrobial nature (associated with the usual microbiome 
of the colon). Based on existing reports, Cd-associated reactive arthritis has the following characteristics: it 
is unrelated to the presence/absence of the MHC-B27 status of the affected patient, arthritis is generally 
polyarticular and fever may or may not be present [9,10]. The tibiofemoral joint (in the knees) and the 
condyloid-type joint in the wrist were the most commonly affected joints [9–12]. The onset of reactive 
arthritis was-on average-around eleven days following the occurrence of diarrhea. The disease took around 
4–5 weeks to resolve, therefore, it may be considered a prolonged condition [9–11]. If diarrheal illness or the 
isolation of Cd does not take place (culture negativity and no clinical suspicion), rare clinical entities in 
children and adults caused by Cd (prosthetic device infections, osteomyelitis, necrotizing fasciitis and 
cellulitis) may be very difficult to ascertain [9–12]. Infections associated with skin and bone involvement as 
usually preceded by some sort of exogenous trauma: it would be reasonable to suspect that the development 
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of extraintestinal Cds (ECDs) may be due to the contamination of the infected site by Cd spores of 
environmental or patient-related origin. [9]. It may, however, also cause disease in a variety of other organ 
systems [10–12]. Nevertheless, additional extraintestinal Cd (EID) manifestations have also been described: 
cellulitis [9], prosthetic and periprosthetic joint infections [11–14], bone infections [15,16], splenic and cranial 
involvement in the form of abscess formation [17–19], pericarditis [20] and infections of the serous 
membrane of the pleura [21], while case-report-based evidence for fasciitis necrotisans [22,23], visceral 
abscesses [18], empyema [24] and appendicitis [25] have also been reported in the literature as uncommon 
presentations of extraintestinal CDIs. Of these extracolonic infections, most were polymicrobial and 
commonly involved the enteric flora [9,21]. Simpson et al. [24] reported one case of CDI in empyema, where 
the proposed route of infection was a chest tube, leading into a pre-existing empyema. However, association 
between stool positivity and clinical presentation could not be established, as no stool samples were sent 
for culture. [24] The only other mechanism through which the pleural fluid could be contaminated is 
hematogenous spread [21]. 
It is important to report that most cases of extraintestinal CDI were polymicrobial in nature, Marina et 
al. [26] reported on anaerobic pleuropulmonary infections and found that of 116 organisms isolated, only 
two were Cd and only one of these was isolated in a pure culture. Roy et al. [27] described a patient presented 
with hepatic and pancreatic abscess with a polymicrobial infection. With the findings of sigmoid 
perforation, they considered the route of infection being translocation of bacteria across the gastrointestinal 
lumen due to colonic inflammation with direct seeding to the site. Direct spread of Cd from the intestine 
has been reported in previous case reports as well, where intra-abdominal spread of infection was suspected 
due to transient bacteremia in a case of alcoholic cirrhosis, with Cd isolated from ascites fluid, but in this 
patient, blood cultures remained negative [28]. Cd is rarely identified as a cause of pyogenic liver abscess, 
there are only three reported case of liver abscesses due to Cd, Sakurai et al. [29] and Ulger et al. [30] have 
reported liver abscess due to the organism. In the publication of Sakurai et al., a case of monomicrobial 
infection in a 75-year-old woman was reported, who had a prior drainage of a hemorrhagic liver cyst and 
was readmitted 2 years later with fever and no reported diarrhea in the patient [29]. Ulger et al. reported a 
case of liver abscess in an 80-year-old, non-hospitalized female, who had no reported diarrhea or antibiotic 
use prior to diagnosis of multiple liver abscesses due to the organism [30]. Morioka et al. [31] described a 
case of a 74-year-old male with primary biliary cirrhosis and hepatocellular carcinoma, who underwent 
transarterial chemoembolization (TACE). One month after hospitalization, the patient was re-admitted due 
to a liver abscess at the same site of the TACE. Cd was isolated solely from the liver abscess and both of 
anaerobic blood cultures were positive after 13-h incubation. At this time GDH and toxin A/B showed 
positivity in the stool samples; but the patient had no apparent diarrhea since then. Toxin A and B and 
binary toxin production all of strains isolated from the blood and liver abscess were identified by PCR using 
nonrepeating sequences of toxins A and B and the repeating sequence of toxin A and cdt (binary toxin): all 
strains tested were positive for toxin A, toxin B and binary toxin [31]. 
There are only a few retrospective studies involving patients with extraintestinal CDIs at a single 
institution over the past decade, aiming to better characterize the syndrome and to correctly establish the 
real incidence. In their first report (chronologically), Smith and King [6] published a total of eight strains of 
Cd, which were isolated from cases of infections in humans from seven different bacteriological laboratories. 
One of these was isolated from a case of gas gangrene, one from an abscess following a fractured femur, 
one from a blood culture from an infant, two from pleural fluid, two from peritoneal fluid and one from an 
abscess in the vaginal vault. According to their findings there was no evidence (in those cases), that Cd is 
pathogenic for man [6]. The role of intermittently occurring Cd bacteremia was highlighted as an important 
factor of transmission from colonic to extracolonic infections such as osteomyelitis, visceral abscess and 
prosthetic joint infections, however, blood cultures positive for Cd have rarely been reported. In 1995, in a 
report published by Chatila and Manthous [32] including four patients, and three additional cases 
published by Lowenkron et al. in 1996 [33], sepsis-like condition of the patients were reported, in 
conjunction with severe pseudomembranous colitis, resulting in the rapid deterioration of the patients; 
these patients needed mechanical ventilation, administration of broad-spectrum antibiotics and support for 
hypotension. Although positive blood cultures were not reported, it was suggested that the sepsis-like 
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syndrome in these patients was associated with Cd, originating from a cellular inflammatory response to 
either severe enterocolitis alone or to other factors such as toxin A and B activation of a host monocyte and 
neutrophilic chemoattractant response [32,33]. Based on these reports, the systemic inflammatory reaction 
(SIRS) may be due to the diffusion of the bacterial toxins across the damaged gut mucosa (with increased 
permeability) [32,33]. Fifteen cases of Cd bacteremia (published in English by 2009) were summarized by 
Libby et al. [34]. The first report was in 1962 in a 5-month-old baby presenting with a cough, inflammation 
of the mucous membranes lining the nasal cavity and loss of appetite [6]. Twelve out of the fifteen cases had 
presented with Gram-negative and/or anaerobic bacteremia, representing bacteria from the gut flora, while 
all cases of Cd bacteremia in adults had some kind of gastrointestinal illness of varying severity; 12 out of 
15 patients reported prior antibiotic exposure. Two patients with polymicrobial Cd bacteremia were affected 
by blood cancer, while one patient had two separate episodes of Cd bacteremia, during which the status of 
the GI-disease of the patient worsened [34]. 7-day mortality was 50% (n = 7), two patient outcomes were 
unknown, while n = 5 patients were discharged from the healthcare facility. The results from stool toxin 
assays were described in only three cases. All but three of the 15 cases of Cd bacteremia were polymicrobial, 
all cases of monomicrobial Cd bacteremia were in adult patients with similar symptoms (concomitant fever, 
abdominal pain and diarrhea) [34]. Cd bacteremia was also noted in a female patient (suffering from 
leukemia), lacking classical gastrointestinal symptoms or radiological findings of colitis or any ongoing 
gastrointestinal pathology [34]. Dauby et al. recently reported a case of monomicrobial bacteremia due to 
Cd and identified the strain as ribotype 002 [28]. Cd bacteremia has been reported in 27 adult patients with 
gastrointestinal disease since 2011 and most of these cases involved polymicrobial bacteremia [32–35]. 
Overall, the mortality rate among patients with Cd bacteremia may be estimated to be around 20%–40%, 
based on published reports [32–35]. 
In a review from the United States, identifying seventeen published cases of extraintestinal Cd (ECD) 
infection [36], the bacteria were isolated from the following sample types: pleural fluid, peritoneal fluid, 
peripheral blood and biopsy of the bones, in addition to abscesses of the spleen, vagina and thigh. In 
contrast, only in three out of 17 cases were reported, when ECD was associated with the detection of Cd 
toxin in the stool sample. A report from a tertiary-care teaching hospital in Madrid, Spain also identified 
seventeen cases of extracolonic Cd over a 10-year period [37]. Cd isolates in twelve patients were originating 
from samples obtained from close anatomical proximity to the colon. Five cases of peritonitis in five cases 
(three primary and two secondary), four cases of intra-abdominal abscesses and four cases of abdominal 
wound infections were the most significant finding, while five other patients had infections not in anatomic 
vicinity of the large intestine (a brain abscess, two bacteremic episodes and two cases of infected lower 
limbs) [37]. Most of the reported isolates were non-toxigenic (verified by the fact that diarrhea was not 
reported in these patients during these pathologies) and patients had no prior antibiotic therapy in their 
anamnestic data; 9/17 (53%) of patients survived [37]. Nevertheless, death could not be directly attributed 
to Cd in any of the cases. In another paper from the Alabama, USA [38], fifty-nine cases of extraintestinal Cd 
infections were reported that might be grouped into three main clinical presentations: bacteremia (in the 
presence or absence of evidence regarding focal infections), intra-abdominal infections and abscess 
formation outside of the abdominal cavity. Cd strains were isolated as a part of a polymicrobial flora in the 
majority (68%) of cases (mainly associated with bacteremia or abscesses, in 40/59 cases) [38]. There is 
evidence that Cd has the ability to potentate infections in polymicrobial infectious processes [38]. While 
more than two-thirds of affected patients presented with serious underlying conditions (e.g., cancer and 
renal failure) or interventions, ~30% did not have any of the specific predisposing factors. It has been 
hypothesized that after the damage and breakdown of the physiological mucosal barrier in the intestines, 
Cd may gain access to the systemic circulation or the abdominal cavity. However, the interpretation of this 
phenomena remains difficult, as presented in the publication, GI symptoms were not present (16 cases) or 
not specifically reported (17 cases) in a high number of patients. Likewise, diarrheal illness was not reported 
in 18/59 cases with extraintestinal infection; overall mortality in this paper was reported to be 37% [38]. A 
significant drawback of most of the reports detailing ECD cases is that toxin-production assays (which may 
be considered the principal virulence factor for Cd) are infrequently performed; however, in the relatively 
low amount of papers where this data is available, these infections are usually caused by non-toxigenic 
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strains. A landmark study from Minneapolis, USA [39] reported that the levels of immunoglobulin G 
antibodies against toxin A was 20-fold higher, in contrast, levels of immunoglobulin A antibodies were 
three-fold higher in a patient who developed a splenic abscess due to a Cd infection, compared to the mean 
levels of the “control” group of patients (n = 14), who presented with Cd diarrhea only. However, the role 
and clinical significance of these naturally occurring antibodies during the progression of the ECD 
infections is not yet known [39]. Visceral abscess formation is usually due to hematogenous spread of 
microorganism, mainly involving the spleen, with one reported case of pancreatic abscess formation [17,39]. 
Frequently, these abscesses are only recognized weeks to months after the onset of diarrhea or other colonic 
symptoms [17,18,39]. 
In a 10-year retrospective, single-center survey performed by Mattila et al. [40], only 0.17% of the CDI 
cases were reported to be extraintestinal. As reported in their study, 81% of the cases were inpatient and 
had received antibiotics, which increased the risk of infection. ECD was found in 31 patients: two patients 
had bacteremia, four had abdominal infections without any prior surgery, seven had abdominal infections 
after surgery, four had a perianal abscess, 13 had wound infections and one had Cd in a urinary catheter 
[40]. From the Mayo Clinic Rochester, Gupta et al. [41] reported their single-center experience in evaluating 
the clinical burden of ECD, and they have also characterized the clinical management and patient outcomes 
of these infections. A retrospective review of available medical records was conducted, identifying patients 
with Cd from extraintestinal sites between 2004 and 2013; overall, 40 patients with extraintestinal CDI were 
identified, out of which twenty-five had abdomino-pelvic infections, eleven had bacteremia, three had 
wound infections and one had a pulmonary infection [41]. Cd was isolated alone in 37% of cases, with 85% 
of infections being reported of nosocomial origin. Indicators associated with the high-risk for extraintestinal 
CDI infections identified in this paper were the following: GI surgery (88%), recent use of broad-spectrum 
antimicrobials (88%), cancer (solid tumors; 50%) and the use of drugs affecting the GI tract (i.e., H+/K+ 
ATPase-inhibitors, 50%). Loose stools were recorded in 18/40 patients, while in 12/40 presented with fecal 
samples PCR-positive for Cd. Resistance to metronidazole and piperacillin-tazobactam in these isolates 
were 0% [41]. In this report, 39/40 patients received antibiotics, in addition to guided drainage of the 
infection site; during the study Gupta, et al. reported a mortality rate of 10/40 patients (25%), the death of 
the patients occurred at a median of around two weeks (range: 1–61 days), after the subsequent isolation of 
Cd [41]. 
All of the abovementioned studies are in agreement regarding the identified risk factors for 
extraintestinal CDIs, namely the immunocompromised status of the patient, surgical manipulation of the 
gastrointestinal tract, recent multiple- or broad-spectrum antibiotic exposure and recent hospitalization. 
However, it is also noteworthy that except for cases involving the small intestine and reactive arthritis, most 
of the cases of extracolonic Cd disease did not appear to be strongly related to previous antibiotic exposure. 
In addition to these well-known risk factors, Mutlu et al. [42] also reported the alteration of the colonic 
microbiome in alcoholics, which was noted to be similar to the enteritis due to Cd colitis, suggesting alcohol 
abuse as a possible risk factor for ECD [42]. As seen in the previous studies, there are some reports available 
on extraintestinal Cd infections, however, the extension of the infection beyond the intestinal tract has not 
been well understood; therefore, the organism at an extraintestinal site is often a surprise. In addition, 
extraintestinal Cd infections are usually found in conjunction with other microorganisms [9–42]. The 
increasing evidence and amount of reports of extraintestinal infection due to Cd should be seen as a warning 
sign, as these uncommon infections are characterized by poor outcome with a high mortality rate. The 
therapy of extraintestinal CDIs is similar to those of enteric infections (antimicrobial therapy) in 
combination with surgical debridement, if necessary [9–42]. There were several reports on extraintestinal 
CDI cases, where non-toxin producing strains were presenting as significant pathogens, therefore, 
suggesting that unspecified virulence factors may be important in promoting extraintestinal infection by 
this microorganism. Therefore, further studies are indicated to better identify these potential virulence 
factors. 
The comparative analysis of the antimicrobial susceptibility and toxin-production of Cd isolates of 
extraintestinal and intestinal origin was not a part of this present study; in addition, our institution does not 
perform routine susceptibility-testing from diarrheal Cd isolates. Toxin-positivity of stool samples received 
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by the institute during the study period was between 20% and 25% (unpublished data). However, over the 
10-year period, susceptibilities of diarrheal Cd isolates were studied in epidemiological studies in Szeged 
and other cities in Hungary, spanning a shorter time periods. Between 2006 and 2007, laboratories from 
West, Central and Southeast Hungary collected n = 150 Cd isolates from diarrheal feces [43]: 80% of isolates 
were positive for toxin A and toxin B (this number was 70.5% between 2002 and 2003 [44]), while resistance 
rates were 0%, 6.3%, 25.0% and 37.5% for MET, RIF, moxifloxacin (MOX) and erythromycin (ERI), 
respectively [43]. In a study spanning between 2008 and 2010, the resistance levels of n = 188 toxin-
producing Cd isolates (originating from three centers in Hungary, including Szeged) were 0%, 0%, 14.9% 
and 19.7% for MET, VAN, RIF and MOX, respectively [45]. In addition, fidaxomicin susceptibilities were 
also tested, and the majority of isolates (97.9%) exhibited low MIC values. In the same time period, the 
results of a different study, reporting on the susceptibility of non-027 PCR ribotype strains (to avoid over-
representation of this outbreak strain) showed resistance levels to be 0%, 21.5%, 29.5% and 31.0% for MET, 
MOX, CLI and ERI, respectively [46]. While between the first two study periods (2002–2003 vs. 2006–2007), 
an increasing tendency in the MICs was recorded, such increase was not observed between the second and 
third period (2006–2007 vs. 2008–2010) [43–46]. 
4. Materials and Methods 
4.1. Study Design and Data Collection 
This retrospective observational study was performed on the basis of microbiological data collected 
regarding a 10-year time frame (from 1 January 2008 to 31 December 2017). The Institute of Clinical 
Microbiology is the dedicated microbiological diagnostic laboratory of an 1820-bed tertiary-care university-
teaching hospital in Szeged, Hungary. This clinical center is responsible for the medical care of over 600,000 
patients in the southeast region of Hungary (population: around 1.3 million people based on the most recent 
census data) [47,48]. Additionally, during the study period, the Institute was also working as the National 
Reference Laboratory of Human Pathogenic Anaerobic Bacteria in Hungary. Data were collected by an 
electronic search of the Institutional laboratory information system (LIS) records for the designated time 
period. The inclusion criterion for analysis was the detection of Cd from an extraintestinal sample in the 
abovementioned study period (2008–2017) [37]. Polymicrobial infection was defined as the isolation of more 
than one organism in a single sample. As a part of this study, data on the affected patients were also 
collected, which was limited to their demographic characteristics only (age, sex and inpatient/outpatient 
status), the basic the indication for sample submission, underlying conditions and the sample origin [48]. 
The study was deemed exempt from ethics review by the Institutional review board and informed consent 
was not required as data anonymity was maintained. 
4.2. Identification of Isolates 
Cd strains were isolated from extraintestinal sites using conventional, routine methods in anaerobic 
bacteriology, according to standard descriptions [49,50]. These methods were not specifically designed to 
detect Cd strains only, but rather to detect all of the culturable anaerobic bacteria in these samples [51]. 
Sample preparation and microbiological culture were carried out according to the routine microbiological 
practice [49,50]. Briefly, samples were suspended in 1 mL of pre-reduced brain–heart infusion broth (BHI, 
with a pH set at 7.2; Oxoid, Basingstoke, UK), which was plated immediately on the appropriate selective 
and non-selective culture media. The following media was used for the quantification of total cultivable 
facultative and anaerobic bacterial flora: Columbia agar base (Oxoid, Basingstoke, UK) supplemented with 
5% (v/v) defibrinated bovine blood, hemin and vitamin K1 [8,49]. The incubation for the isolation of aerobic 
bacteria was carried out at 37 °C in a 5% CO2-containing environment for 48 h. For the isolation of anaerobes, 
bacterial cultures were set up and incubated in an in an anaerobic environment (containing an atmosphere 
of 90% N2, 5% H2 and 5% CO2; (Baker Ruskinn, York, UK) for 2–5 days at 37 °C. Isolation of Cd from 
peripheral blood samples was performed using the BacT/ALERT Culture Media system (bioMérieux, 
Marcy-l’Étoile, France). Isolation of Cd in stool samples was carried out using Cd–selective Brazier CCEY 
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agar (cefoxitin-cycloserine-egg yolk-agar, Mast Diagnostics, Bootle, UK) at 37 °C for 42 h in an anaerobic 
atmosphere. Colonies with typical morphology, fluorescence and odor were presumptively identified as 
Cd, which was verified by biochemical and MALDI-TOF MS [8,49]. 
During the identification of the isolates, Gram-staining and growth requirements for each individual 
colony type (identified phenotypically using a colony microscopy) provided the basis for choosing the 
relevant biochemical identification tests to be used. The identification of bacterial and fungal isolates was 
carried out using classical biochemical tests and ATB/VITEK (bioMérieux, Marcy-l’Étoile, France) and 
matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (instrument: Microflex 
MALDI-TOF MS Biotyper (Bruker Daltonics Gmbh., Bremen, Germany) software: MALDI Biotyper Library 
3.1); the sample-preparation methods and the technical details of the measurements were performed as 
previously described [52]. 
4.3. Determination of Toxin Production and Ribotyping, Antibiotic Susceptibility Testing 
Toxin production of the isolates was tested using an immunochromatographic method, detecting toxin 
A and toxin B (C. difficile QuikChek Complete, Techlab, Blacksburg, VA, USA). Samples with a GDH-
positive, but toxin A/B negative results were further tested with the TC (toxigenic culture) method [44]. 
Strain typing was performed by PCR ribotyping method as described by Stubbs et al. [53]. 
Metronidazole (MET), vancomycin (VAN), clindamycin (CLI) and rifampicin (RIF) susceptibility of the 
isolates were tested using the E-test methodology (AB BIODISK, Solna, Sweden). A Cd suspension (of 0.5 
McFarland turbidity) of each strain was swabbed on Brucella agar (Oxoid, UK) supplemented with 5% 
defibrinated sheep blood, 1 mg/L hemin and 5 mg/L Vitamin K1 [50]. E-test strips of MET, VAN, CLI and 
RIF were applied onto the agar surface and the plates were incubated in an anaerobic atmosphere for 24–
48 h. MICs were read at the point at which the zone of complete inhibition intersected the MIC scale. For 
the evaluation of the susceptibility of the tested isolates, EUCAST breakpoints and epidemiological cut-off 
values (in case of RIF) were used (http://www.eucast.org). C. difficile ATCC 9689, C. perfringens ATCC 13,124, 
B. fragilis ATCC 25,285 and C. acnes ATCC 11,827 were used as control strains. 
5. Conclusions 
Results from our 10-year retrospective study further highlight the low incidence of extraintestinal CDI 
(0–4 cases/year in our settings), corresponding to 0.58% of total isolations of C. difficile between 2008 and 
2017. Their isolation in from extraintestinal samples was frequently associated with gastrointestinal tract 
surgery and other well-known risk factors for intestinal CDI. Interestingly, 36.7% of the patients were 
outpatients and four of them had some form of skin and soft tissue infection. In most cases, C. difficile strains 
were members of the mixed aerobic/anaerobic flora, with only n = 4 specimens where the C. difficile strain 
was the sole pathogen. The most common co-pathogens were E. coli and E. faecalis/faecium, while only four 
anaerobic pathogens were present as co-pathogens with C. difficile. The toxin production of the strains was 
determined in 19 isolates and 79% proved to be a toxin A and B-producing strain, while for 50% of the 
strains, ribotyping was also performed and three strains were identified as the rare, 198 (Hungarian: Szeged) 
PCR ribotype. Antibiotic susceptibility of the strains was high to the tested antibiotics. Although the number 
of isolates were low during the study period (similarly to other publications in the literature), the present 
paper reports on a decade’s worth of data from a tertiary-care teaching hospital, in addition to presenting a 
literature summary of the available references on the topic. 
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